This webinar will address when and why external control arms (ECA) are used, the acceptable types of data and methods to build ECAs, and circumstances under which ECAs are accepted from regulatory and HTA bodies.
Sponsored by Lane Clark & Peacock LLP
In this webinar, we will give an overview of LLMs and share practical advice and cutting-edge examples about how to use them to help carry out real-world evidence (RWE) studies. We will also show how integrating GPT into population health analytics enables complex real-world datasets to be explored using simple language queries to transform the way that decision makers use data to identify unmet health needs.
Sponsored by Optum
This webinar is aimed at those who perform or use the results of real-world evidence (RWE) studies. It aims to describe the use of predictive analytics and machine learning for causal inference in the context of the extremes for disease populations: rare diseases and common conditions such as obesity.
In oncology, sequential use of treatments with different mechanisms of action is common practice to overcome cross-resistance . Over the past decade, treatment sequencing with novel immunotherapy and targeted agents has contributed to substantial improvement in clinical outcomes in cancer patients. However, such clinical practice introduces methodology challenges for HTA.
In this forum, the OSM Special Interest Group has selected leaders in the field of health economics to describe their approach to OSMs. Mohsen Sadatsafavi will introduce the Peer Models Network and PRISM service as part of "Open-access modelling as a companion to open-source modelling” illustrated with an example implemented for Chronic Obstructive Pulmonary Disease (the Evaluation Platform in COPD (EPIC) model.)
Sponsored by FIFARMA
This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".
Sponsored by Evidera, a PPD Company
This webinar will explore what the SUCRA is, demonstrate how it can be meaningfully impacted by network composition (even in simple networks), and suggest corrections to common errors in the reporting of SUCRAs.
Sponsored by Replica Analytics
This webinar presents a brief tutorial on synthetic data generation, an overview of its privacy preserving properties, and then review the results from studies evaluating the validity of analyses using synthetic data.
The Statistical Methods in Health Economics and Outcome Research Special Interest Group is pleased to present two webinars on Network Meta-Analysis (NMA). The first one is an introduction to NMA by Emma Hawe. The second will cover special topics in NMA by Sofia Dias. Both webinars will be moderated by Gian Luca Di Tanna. The second webinar will feature more advanced content than the first webinar.
The Statistical Methods in Health Economics and Outcome Research Special Interest Group is pleased to present two webinars on Network Meta-Analysis (NMA). The first of two webinars will focus on the terms associated with network meta-analyses, how and why different comparisons are used, and the concepts, assumptions, and limitations associated with NMA. The first webinar is focused on an Introduction to NMA by Emma Hawe. The second will cover special topics in NMA by Sofia Dias. Both webinars will be moderated by Gian Luca Di Tanna.
This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).
Sponsored by MDClone
Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.
Sponsored by Biogen
This session educates about the specific challenges of rare disease treatments in an HTA and discusses how Real-World Evidence Collection can address the data gap at the time of access decision.
Many preference researchers have been quick to respond to this need and have conducted empirical COVID19 studies to better understand the value of health and health-related policies.
In this webinar, we will consider the apparent disconnect between HTA assessments of treatments within a specified location in a treatment sequence and clinical practice where a treatment sequence is tailored to the patient.
Determining resource utilization patterns, treatment and disease-related costs has become an important aspect of health outcomes research to guide health care resource allocation from a payer and policy decision-making perspectives.